Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B‐cell lymphoma
Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B‐cell lymphoma
复制标题
DOI：
10.1002/hon.940
复制
发表时间：
2010-06
影响因子：
3.3
通讯作者：
N. Niitsu;M. Kohri;Yuki Hagiwara;Ken Tanae;N. Takahashi;M. Bessho;M. Okamoto
中科院分区：
文献类型：
--
作者：
N. Niitsu;M. Kohri;Yuki Hagiwara;Ken Tanae;N. Takahashi;M. Bessho;M. Okamoto
已发现R-CHOP方案可改善弥漫性大B细胞淋巴瘤(DLBCL)的预后。然而，在高危人群中，它并没有提供令人满意的治疗结果。我们以前给DLBCL患者使用了CyclOBEAP方案，并报告了它的安全性和有效性。R-CyclOBEAP方案共用药12周，利妥昔单抗375 mg/m2每2周给药一次。符合条件的患者101例。96例患者(95%)获得完全缓解。5年总生存率为85%，无进展生存率为76%。当根据IPI对患者进行分类时，风险组之间的5年OS率和PFS率没有显著差异。生发中心B细胞组5年生存率为80%，非GCB组为74%(NS)。单因素分析显示，B症状、结外病变≧-2、sIL-2R是影响预后的显著因素。中性粒细胞减少4级91例，血小板减少9例。在CyclOBEAP治疗的基础上加用利妥昔单抗，可提高CyclOBEAP治疗DLBCL的疗效。版权所有©2010 John Wiley&Sons，Ltd.
The R‐CHOP regimen has been found to improve the outcome of diffuse large B‐cell lymphoma (DLBCL). However, it does not provide a satisfactory treatment outcome in the high‐risk group. We previously administered the CyclOBEAP regimen to patients with DLBCL, and reported its safety and efficacy. The R‐CyclOBEAP regimen was administered over a total period of 12 weeks, and rituximab 375 mg/m2 was given every 2 weeks. There were 101 eligible patients. CR was achieved in 96 patients (95%). The 5‐year overall survival (OS) rate was 85% and progression‐free survival (PFS) rate was 76%. When the patients were divided according to the IPI, the 5‐year OS and PFS rates did not significantly differ among the risk groups. The 5‐year PFS of the germinal centre B‐cell group was 80% and that of the non‐GCB group was 74% (NS). Univariate analysis showed that the presence of B symptoms, extranodal lesions ≧2, and sIL‐2R were significant poor prognostic factors. Grade 4 neutropenia was observed in 91 patients and thrombocytopenia in 9 patients. The addition of rituximab to CyclOBEAP therapy may enhance the effect of CyclOBEAP therapy for DLBCL. Copyright © 2010 John Wiley & Sons, Ltd.